The only thing one can do with good advice is to pass it on. It is never of any
use to oneself.
Oscar
Wilde, 19th Century Playwright & Author.
Ranked quarterly according to Net Income, based on
Trailing Twelve Months (TTM).
Key: 
or 
=
quarterly performance trends.
Revised: 10 July 2025.
Click on "Name; Location" for company websites & "SYMBOL
Chart" for
TradingView
profiles.
|
Primary
Market Color Key: |
|
Biopharmaceuticals |
Genetics |
Instrumentation,
Software, & Reagents |
Stem Cell/Cellular Therapy |
Gene
Therapy |
|
ThermoFisher Scientific, Inc.;
MA
|
Gilead Sciences, Inc.; NoCal
|
Amgen, Inc.; SoCal
|
|
Biogen, Inc.; MA
|
Agilent Technologies, Inc.;
NoCal
|
Quest Diagnostics, Inc.; NJ
|
|
Laboratory Corporation of America; NC
|
Avantor, Inc; PA
|
Exelixis, Inc.; NoCal
|
|
PTC Therapeutics, Inc.;
NJ
|
BioMarin Pharmaceutical, Inc.; NoCal
|
QIAGEN, NV; NLD
|
|
Incyte Corp.; DE
|
Lineage Cell Therapeutics, Inc.;
SoCal
|
Pluri, Inc.; ISR
|
|
Precision BioSciences, Inc.;
NC
|
BioCryst Pharmaceuticals, Inc.;
NC
|
Affimed GmbH; DEU
|
|
Sangamo Therapeutics, Inc.; NoCal
|
Myriad Genetics, Inc.; UT
|
Geron Corp.; NoCal
|
|
Legend Biotech Corp.; NJ
|
Editas Medicine, Inc.; MA
|
Alnylam Pharmaceuticals, Inc.;
MA
|
|
CRISPR Therapeutics AG;
CHE
|
Ionis Pharmaceuticals, Inc.;
SoCal
|
Intellia Therapeutics, Inc.;
MA
|
|
Illumina, Inc.; SoCal
|
Vertex Pharmaceuticals, Inc.; MA
|
Moderna, Inc.; MA
|
|
Chart updates courtesy of
TradingView © 2025 |
|
Primary
Market Color Key:
|
|
Biopharmaceuticals |
Genetics |
Instrumentation,
Software, & Reagents |
Stem
Cell/Cellular
Therapy |
Gene
Therapy |
-
Biotech/Pharma/FDA
News
- Biotech/Pharma
IPO News